|
Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancrea
Celgene International SÃ*rl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.
More... |
| All times are GMT -7. The time now is 08:24 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021